Nearly 30–50% of patients with advanced solid tumors may develop lung metastases during the course of their disease. SBRT & Precision Radiation for Pulmonary Metastases has transformed outcomes for many of these patients by offering highly targeted, non-invasive treatment that can control disease with minimal damage to healthy lung tissue. Under the leadership of Dr Mathangi J, Senior Consultant & In-charge – Radiation Oncology at Gleneagles Cancer Institute, Bangalore, this advanced approach has redefined hope for patients across South India and North India.
Pulmonary metastases occur when cancer cells from a primary tumor—such as breast, colorectal, kidney, or head and neck cancers—spread to the lungs. These secondary tumors can appear as solitary nodules or as multiple pulmonary metastases scattered throughout the lung fields.
They may involve the pulmonary parenchymal metastases, meaning the functional lung tissue itself, and in some cases may present as cavitating pulmonary metastases, where the tumor forms a hollowed-out cavity. Another clinical scenario includes lung to lung metastasis, where cancer originating in one lung spreads to the other.
Each presentation requires a highly individualized pulmonary metastases treatment strategy, and this is where precision radiation becomes crucial.
Stereotactic ablative body radiotherapy (SBRT) delivers very high doses of radiation with sub-millimeter precision over fewer sessions. It is particularly effective for:
Unlike conventional radiation, SBRT focuses on the tumor with remarkable accuracy, sparing surrounding lung parenchyma. For patients with multiple pulmonary metastases, carefully planned SBRT may still be an option depending on disease burden and location.
Precision radiation integrates imaging, motion management, and advanced delivery platforms. At Dr Mathangi’s center, technologies such as Image-Guided Radiotherapy (IGRT), RapidArc, and gated techniques ensure radiation tracks tumor motion during breathing.
This level of accuracy is particularly critical in pulmonary parenchymal metastases, where preserving lung function is paramount.
Dr Mathangi J is a Senior Radiation Oncologist with over 20 years of experience and more than 12,000 successfully treated patients. She completed her DMRT at Madras Medical College and her DNB at Apollo Cancer Specialty Hospital, Chennai. Her advanced training in Stereotactic techniques (SRS/SBRT) from Klinikum Frankfurt (Oder), Germany, IGRT/RapidArc from Copenhagen University Hospital, Denmark, and IORT training have positioned her among India’s leading experts in precision oncology.
She currently heads the radiation oncology department and serves as Director of Fellowship in Advanced Radiotherapy techniques affiliated with RGUHS. Notably, she was instrumental in installing the Asia Pacific’s first TrueBeam STx machine.
When facing something as complex as lung to lung metastasis or cavitating pulmonary metastases, experience is not optional—it is decisive.
Cancers that frequently spread to the lungs include:
Radiation therapy plays a vital role either as definitive, consolidative, or palliative treatment in many of these conditions.
| Feature | Conventional RT | SBRT |
|---|---|---|
| Number of Sessions | 20–30 | 3–5 |
| Precision | Moderate | Sub-millimeter accuracy |
| Dose Per Fraction | Lower | Very high |
| Impact On Healthy Lung | Broader exposure | Highly targeted |
For carefully selected patients with multiple pulmonary metastases, SBRT can achieve local control rates exceeding 80–90% in many clinical studies.
The process is structured, precise, and patient-centric.
Delaying therapy in pulmonary metastases may allow progression from a limited oligometastatic state to widespread disease. Early intervention with SBRT can convert a potentially life-limiting scenario into a controlled condition.
Many patients underestimate symptoms until they experience breathlessness or persistent cough. By then, lesions may have grown or multiplied. Acting early under the guidance of an expert like Dr Mathangi can preserve lung function and extend survival.
Cavitating pulmonary metastases require careful radiation planning because the structural integrity of lung tissue is altered. SBRT’s precise targeting minimizes surrounding damage while delivering ablative doses directly to the tumor cavity margins.
Similarly, lung to lung metastasis demands strategic evaluation to differentiate new primaries from metastatic deposits. Precision imaging and biopsy correlation guide treatment planning.
Patients across India travel to Bangalore seeking her expertise because precision is not just about machines—it is about judgment, planning, and execution.
Dr Mathangi J is a Senior Consultant & In-charge – Radiation Oncology at Gleneagles Cancer Institute, Bangalore. She specializes in Head and Neck Cancers, Prostate Cancers, Brain Tumors, Lung Cancers, and Women Cancers including Breast, Cervix, and Endometrium. Her commitment to academic excellence and patient-centered care positions her as a trusted authority in advanced radiation therapy.
If you or a loved one has been diagnosed with pulmonary metastases, waiting can mean losing the window where precision therapy offers maximum benefit. SBRT & Precision Radiation for Pulmonary Metastases is not merely a treatment option—it can be a turning point.
To book an appointment, submit your contact information at https://drmathangi.com/contact/. Dr Mathangi’s team will schedule your consultation and guide you through the next steps toward personalized, precision-driven cancer care.
Pulmonary metastases are cancerous deposits that have spread to the lungs from another primary tumor, such as breast, colorectal, kidney, or sarcoma. These can involve the lung tissue itself and are often described radiologically as pulmonary parenchymal metastases.
SBRT (Stereotactic Body Radiation Therapy) is recommended when there are a limited number of well-defined lung lesions, when surgery is not feasible, or when patients prefer a non-invasive option. Under the guidance of Dr. Mathangi, treatment decisions are individualized after multidisciplinary evaluation, imaging review, and discussion of systemic therapy status.
Pulmonary metastases treatment with SBRT involves delivering very high doses of precisely targeted radiation to metastatic lung nodules over a few sessions. Advanced imaging, motion management, and image-guided radiation techniques allow accurate targeting while sparing healthy lung tissue.
Dr. Mathangi uses meticulous planning protocols to map the tumor in three dimensions, account for breathing motion, and ensure optimal dose delivery. This precision approach improves local control while reducing side effects compared to conventional radiation schedules.
Yes, SBRT can be considered in selected cases of multiple pulmonary metastases, particularly when the number of lesions is limited and each can be safely targeted. The concept of “oligometastatic disease” plays an important role here.
Dr. Mathangi evaluates factors such as the number of nodules, their size, location near critical structures, prior treatments, and overall disease control before recommending SBRT. In some cases, a combination of systemic therapy and staged SBRT may be advised.
Cavitating pulmonary metastases are lung lesions that develop a hollow or necrotic center. These can arise from certain primary cancers and may present unique imaging features.
SBRT can still be effective in appropriately selected patients. Treatment planning carefully accounts for cavity size, wall thickness, and proximity to airways or blood vessels. With advanced image guidance, Dr. Mathangi ensures that even complex-appearing lesions are evaluated thoroughly before proceeding with precision radiation.
Lung to lung metastasis refers to a situation where a primary lung cancer spreads to another region within the lungs. Although less common than spread from other organs, it requires careful distinction from second primary lung cancers.
In selected patients with limited spread, SBRT may be used to treat discrete lesions. Dr. Mathangi works closely with thoracic surgeons, pulmonologists, and medical oncologists to confirm diagnosis and design the most appropriate radiation strategy.
SBRT is non-invasive, typically completed in 3–5 sessions, and does not require general anesthesia. For patients who are medically inoperable or wish to avoid surgery, it offers an effective alternative with high rates of local tumor control.
Recovery time is minimal, and most patients continue daily activities during treatment. Dr. Mathangi’s precision radiation protocols are designed to minimize exposure to healthy lung tissue, thereby reducing the risk of long-term breathing complications.
Most patients tolerate SBRT very well. Mild fatigue and transient cough are the most commonly reported symptoms. In rare cases, radiation pneumonitis or chest wall discomfort may occur, depending on tumor location.
Before starting therapy, Dr. Mathangi discusses potential risks in detail and implements preventive planning strategies. Regular follow-up imaging and clinical assessments are part of comprehensive care.
Suitability depends on the number, size, and location of lung lesions, overall lung function, control of the primary cancer, and prior treatments received. Imaging studies such as PET-CT and high-resolution CT scans are typically reviewed.
Dr. Mathangi conducts a comprehensive consultation, reviews pathology and imaging, and collaborates with the oncology team to determine whether SBRT offers the best balance of safety and effectiveness for your specific condition.